Novartis Lamisil
Executive Summary
Lamisil DermGel (terbinafine gel) approved July 26 to include tinea cruris. DermGel is currently approved for tinea versicolor, tinea pedis and tinea corporis (1"The Pink Sheet" May 4, 1998, In Brief)
You may also be interested in...
Novartis Lamisil DermaGel
Topical gel formulation of antifungal terbinafine approved April 29. NDA 20-846 provides for treatment of tinea versicolor due to Malassezia furfur (formerly Pityrosporum ovale), tinea pedis (athlete's foot) or tinea corporis (ringworm) due to Trichophyton rubrum, Trychophyton mentagrophytes, or Epidermophyton floccosum. Lamisil DermaGel does not carry an indication for tinea cruris (jock itch), which is included in Lamisil cream labeling...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials